Related references
Note: Only part of the references are listed.Unravelling Intratumoral Heterogeneity through High-Sensitivity Single-Cell Mutational Analysis and Parallel RNA Sequencing
Alba Rodriguez-Meira et al.
MOLECULAR CELL (2019)
Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population
Sabrina Cordua et al.
BLOOD (2019)
Somatic mutations and cell identity linked by Genotyping of Transcriptomes
Anna S. Nam et al.
NATURE (2019)
Improving Gene Editing Outcomes in Human Hematopoietic Stem and Progenitor Cells by Temporal Control of DNA Repair
Anastasia Lomova et al.
STEM CELLS (2019)
Site-Specific Gene Editing of Human Hematopoietic Stem Cells for X-Linked Hyper-IgM Syndrome
Caroline Y. Kuo et al.
CELL REPORTS (2018)
Priming Human Repopulating Hematopoietic Stem and Progenitor Cells for Cas9/sgRNA Gene Targeting
Carsten T. Charlesworth et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2018)
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
William Vainchenker et al.
BLOOD (2017)
Long-Term Engraftment and Fetal Globin Induction upon BCL11A Gene Editing inBone-Marrow-Derived CD34+ Hematopoietic Stem and Progenitor Cells
Kai-Hsin Chang et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2017)
The changing landscape of gene editing in hematopoietic stem cells: a step towards Cas9 clinical translation
Daniel P. Dever et al.
CURRENT OPINION IN HEMATOLOGY (2017)
Customizing the genome as therapy for the β-hemoglobinopathies
Matthew C. Canver et al.
BLOOD (2016)
Efficient introduction of specific homozygous and heterozygous mutations using CRISPR/Cas9
Dominik Paquet et al.
NATURE (2016)
Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells
Mark A. DeWitt et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Improved Human Erythropoiesis and Platelet Formation in Humanized NSGW41 Mice
Susann Rahmig et al.
STEM CELL REPORTS (2016)
Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
A. M. Vannucchi et al.
ANNALS OF ONCOLOGY (2015)
The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis
Michael Deininger et al.
BLOOD (2015)
Effect of Mutation Order on Myeloproliferative Neoplasms
Christina A. Ortmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Myeloproliferative Neoplasms A Contemporary Review
Ayalew Tefferi et al.
JAMA ONCOLOGY (2015)
JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease
Juan Li et al.
BLOOD (2014)
JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate
Camilla Nielsen et al.
HAEMATOLOGICA (2014)
Role of Hematopoietic Stem Cell Transplantation in Patients with Myeloproliferative Disease
Rachel B. Salit et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2014)
Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F
Pontus Lundberg et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Targeted genome editing in human repopulating haematopoietic stem cells
Pietro Genovese et al.
NATURE (2014)
Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase
Yibing Shan et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2014)
Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
Giulio Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms
S. Leah Etheridge et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal
Iman Fares et al.
SCIENCE (2014)
Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera
Ann Mullally et al.
BLOOD (2013)
JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα
Salma Hasan et al.
BLOOD (2013)
DNA targeting specificity of RNA-guided Cas9 nucleases
Patrick D. Hsu et al.
NATURE BIOTECHNOLOGY (2013)
High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity
Vikram Pattanayak et al.
NATURE BIOTECHNOLOGY (2013)
Establishment of Immortalized Human Erythroid Progenitor Cell Lines Able to Produce Enucleated Red Blood Cells
Ryo Kurita et al.
PLOS ONE (2013)
Critical requirement for Stat5 in a mouse model of polycythemia vera
Dongqing Yan et al.
BLOOD (2012)
Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2V617F in mice
Christoph Walz et al.
BLOOD (2012)
Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F
Rajintha M. Bandaranayake et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2012)
Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice
Caroline Marty et al.
BLOOD (2010)
Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease
Hajime Akada et al.
BLOOD (2010)
JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia
Juan Li et al.
BLOOD (2010)
Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells
Ann Mullally et al.
CANCER CELL (2010)
Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo
Nathalia Holt et al.
NATURE BIOTECHNOLOGY (2010)
The 2008 World Health Organization Classification System for Myeloproliferative Neoplasms Order Out of Chaos
Ayalew Tefferi et al.
CANCER (2009)
Janus kinases in immune cell signaling
Kamran Ghoreschi et al.
IMMUNOLOGICAL REVIEWS (2009)
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice
Ralph Tiedt et al.
BLOOD (2008)
The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis
Juergen Thiele et al.
Current Hematologic Malignancy Reports (2008)
Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms
A. Tefferi et al.
LEUKEMIA (2008)
Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis
Francois Delhommeau et al.
BLOOD (2007)
Molecular Pathogenesis and Therapy of Polycythemia Induced in Mice by JAK2 V617F
Virginia M. Zaleskas et al.
PLOS ONE (2006)
Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells
Loic Garcon et al.
BLOOD (2006)
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model
Gerlinde Wernig et al.
BLOOD (2006)
The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation
CHM Jamieson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
JAK2(V617F) expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis
Catherine Lacout et al.
BLOOD (2006)
Identification of an acquired JAK2 mutation in Polycythemia vera
RX Zhao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
STATs: Transcriptional control and biological impact
DE Levy et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2002)
Serum erythropoietin values in erythrocytoses and in primary thrombocythaemia
M Messinezy et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Share Paper
